Your SlideShare is downloading. ×
New Study on R&D Costs Available
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

New Study on R&D Costs Available


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. New OHE Study on Pharmaceutical R&D Costs ReleasedLondon. 3 December 2012. The Office of Health Economics today released a comprehensive studyof the cost of R&D for new medicines. It confirms research published to date, which shows anincrease in costs from £125 million ($199 million) per new medicine in the 1970s to £1.2 billion($1.9 billion) in the 2000s (both in 2011 prices).Four factors are increasing R&D costs: (1) higher out-of-pocket costs, up nearly 600% from the1970s to the 2000s; (2) lower success rates for clinical development as tougher therapeutic areasare tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology—from 1in 5 in the 1980s to 1 in 10 in the 2000s; (3) increases in R&D times as both regulation and sciencehave become more complex, from 6 years in the 1970s to 13.5 years in the 2000s; and (4) increasesin the cost of capital—i.e. providing returns to funders that reflect the high risks of investing inmedicines R&D, from 8% in the 1970s to 11% in the 2000s.Companies continue to emphasise changes that are intended to improve the efficiency of R&Ddecisions, addressing those factors within their control. This includes, for example, makingdecisions far earlier in R&D about the market prospects of a drug candidate and more tightlymanaging clinical trial costs, often by outsourcing some aspects and/or siting some trials in lower-cost locations.Rapidly evolving R&D technology requires a wide range of expertise and data. New collaborationsare arising that involve a range of public and private entities, sharing both risks and rewards. DrMestre-Ferrandiz, lead author on the study, points out that ‘Just as new approaches to R&D arecrucial to the future, so are new approaches to facilitating market entry and use. These areessential both to encouraging R&D and ensuring that patients have the earliest access possible tolife-changing therapies’.Contact: Jorge Mestre-FerrandizEmail: jmestre-ferrandiz@ohe.orgPhone: +44.20.7747.8860Materials: Office of Health Economics is a research and consulting organisation that has been providingspecialised research, analysis and expertise on a range of health care and life sciences issues andtopics for 50 years. Visit us on the web at of Health Economics • Southside, 7th Floor • 105 Victoria Street • London SW1E 6QT • UK